ATE251613T1 - Pyrimidinonderivate zur behandlung von atheroscleros - Google Patents

Pyrimidinonderivate zur behandlung von atheroscleros

Info

Publication number
ATE251613T1
ATE251613T1 AT99942894T AT99942894T ATE251613T1 AT E251613 T1 ATE251613 T1 AT E251613T1 AT 99942894 T AT99942894 T AT 99942894T AT 99942894 T AT99942894 T AT 99942894T AT E251613 T1 ATE251613 T1 AT E251613T1
Authority
AT
Austria
Prior art keywords
group
bond
formula
ring system
conh
Prior art date
Application number
AT99942894T
Other languages
English (en)
Inventor
Colin Andrew Leach
Stephen Allan Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818375.9A external-priority patent/GB9818375D0/en
Priority claimed from GBGB9902009.1A external-priority patent/GB9902009D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE251613T1 publication Critical patent/ATE251613T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99942894T 1998-08-21 1999-08-18 Pyrimidinonderivate zur behandlung von atheroscleros ATE251613T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9818375.9A GB9818375D0 (en) 1998-08-21 1998-08-21 Novel compounds
GBGB9902009.1A GB9902009D0 (en) 1999-01-29 1999-01-29 Novel compounds
PCT/EP1999/006093 WO2000010980A1 (en) 1998-08-21 1999-08-18 Pyrimidinone derivatives for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
ATE251613T1 true ATE251613T1 (de) 2003-10-15

Family

ID=26314252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942894T ATE251613T1 (de) 1998-08-21 1999-08-18 Pyrimidinonderivate zur behandlung von atheroscleros

Country Status (6)

Country Link
US (1) US6559155B1 (de)
EP (1) EP1105377B1 (de)
JP (1) JP2002523402A (de)
AT (1) ATE251613T1 (de)
DE (1) DE69911980T2 (de)
WO (1) WO2000010980A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009739A (pt) 1999-04-13 2002-04-09 Basf Ag Composto, medicamento, preparação farmacêutica, e, usos de um elemento estrutural, de um composto e de uma preparação farmacêutica
GB9910079D0 (en) * 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
DE60042286D1 (de) * 1999-05-01 2009-07-09 Smithkline Beecham Plc Pyrimidinon Verbindungen
GB9910378D0 (en) * 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
DE60139429D1 (de) * 2000-02-16 2009-09-10 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
FR2815345B1 (fr) * 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
US6939863B2 (en) 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
BRPI0721697A2 (pt) 2007-05-11 2014-08-05 Univ Jefferson " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
CA2759187A1 (en) * 2009-04-03 2010-10-07 Medisyn Technologies, Inc. Compositions for treatment of alzheimer's disease
US8637536B2 (en) * 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
WO2012075917A1 (en) * 2010-12-06 2012-06-14 Glaxo Group Limited Compounds
EP2651403B1 (de) 2010-12-17 2020-12-02 Glaxo Group Limited Verwendung von lp-pla2-inhibitoren zur behandlung und vorbeugung von augenerkrankungen
US9273054B2 (en) * 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
EP2739627A4 (de) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-dihydroimidazo-[1,2-c-] pyrimidin-5 (1h)-on-verbindungen als lp-pla²- inhibitoren
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
JP2016505053A (ja) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物
WO2014114694A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN114805389B (zh) 2019-11-09 2023-08-29 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
WO2024196698A2 (en) * 2023-03-17 2024-09-26 Curadh Mtr Compounds and constructs useful for targeting fibroblast activation protein
JP2026516205A (ja) 2023-04-18 2026-05-20 サイニューロ セラピューティクス インコーポレイテッド Ｌｐ－ｐｌａ２阻害剤と第２の薬剤の併用治療
CN118221687B (zh) 2023-07-17 2024-12-31 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145546A (en) 1975-10-02 1979-03-20 Smith Kline & French Laboratories Limited 4-Pyrimidone compounds
US4154834A (en) 1975-12-29 1979-05-15 Smith Kline & French Laboratories Limited Substituted isocytosines having histamine H2 -antagonist activity
WO1999024420A1 (en) * 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP2002523402A (ja) 2002-07-30
DE69911980D1 (de) 2003-11-13
US6559155B1 (en) 2003-05-06
WO2000010980A1 (en) 2000-03-02
EP1105377A1 (de) 2001-06-13
EP1105377B1 (de) 2003-10-08
DE69911980T2 (de) 2004-09-09

Similar Documents

Publication Publication Date Title
DE69911980D1 (de) Pyrimidinonderivate zur behandlung von atheroscleros
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
ATE264846T1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
ATE37375T1 (de) Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva.
TR200201413T2 (tr) Faktör Xa' nın inhibitörleri.
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
ATE86247T1 (de) 3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
BG105112A (bg) Средство с антидепресивно действие
EA200100731A1 (ru) Фенилфенантридины с ингибирующей фдэ-4 активностью
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
BR0010220A (pt) Compostos de pirimidinona
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
ATE323686T1 (de) Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel
EP1318811A4 (de) Cyclopentylmodulatoren der chemokin-rezeptor-aktivität
DE69232929D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
TR199802536T2 (xx) Yeni amino asit t�revleri,trombin inhibit�rleri olarak kullan�lmalar�.
TR200002542T2 (tr) Meta-azasiklik amino benzoik asit bileşikleri ve bunların integrin antagonistleri olan türevleri
DE69815311D1 (de) Substituierte derivate von benzosulphonamiden als hemmer des enzym cyclooxygenase ii
MX9800186A (es) Derivados de azetidinona para el tratamiento de ateroesclerosis.
TR200001010T2 (tr) Ürokinaz önleyicileri olan izokinolinler.
FR2763949B1 (fr) Compose stabilisant, composition le contenant et procede l'utilisant
EP1422225A4 (de) Benzoisoselenazolderivate mit entzündungshemmender, antiviraler und antithrombotischer wirkung und deren verwendungen
DE69821530D1 (de) Dihydrobenzifurane
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties